Login
$ALKS
$46.53 -$0.50 (1.06%) Live

$ALKS 8-K/A SEC Filings

Filed On Filing
03 Aug 2026 8-K/A: Departure/Election of Directors or Officers; Compensation

As previously disclosed, on February 24, 2026, the Board appointed Mr. Jackson to serve as the Company’s CEO, effective August 1, 2026. On July 28, 2026, the Board took action to expand Mr. Jackson’s responsibilities and, commensurate wi...

01 May 2026 8-K/A: Financial Statements and Exhibits

To the shareholder and the Board of Directors of Avadel Pharmaceuticals plc

20 Sep 2016 8-K/A: Departure/Election of Directors or Officers; Compensation

(d) On September 14, 2016, in connection with the election of Nancy L. Snyderman, M.D. as a Class I director of the Company on May 26, 2016 and consistent with the “Director Compensation” section of the Company’s definitive proxy stateme...

16 Apr 2015 8-K/A: Completion of Acquisition or Disposition of Assets

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

29 Sep 2011 8-K/A: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +5 more

We were previously principal accountants for Alkermes plc (formerly Antler Science Two plc) and, under the date of July 12, 2011, we reported on the balance sheet and related notes of Alkermes plc (formerly Antler Science Two plc)as of J...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support